Company Encyclopedia
View More
name
Gain Therapeutics
GANX.US
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company’s lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher’s disease, lysosomal storage disorders, metabolic disorders, and solid tumors.
1.875 T
GANX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Gain Therapeutics Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson’s Models

    Gain Therapeutics Inc. presented preclinical data on GT-02287 at Neuroscience 2025, showing its potential as a disease-modifying therapy for Parkinson’s. The drug enhances mitochondrial function by facilitating glucocerebrosidase trafficking, reducing mitochondrial stress, and improving neuronal survival in Parkinson’s models. These findings suggest GT-02287 could improve mitochondrial health in patients with GBA1 mutations. The data was shared at the Society for Neuroscience annual meeting in San Diego.

    Reuters·
    US
    GANX
    -4.04%
    Reuters·
    US
    GANX
    -4.04%

    Positive Outlook for Gain Therapeutics: Promising Clinical Trial Results and Stable Financial Health Drive Buy Rating

    BTIG analyst Thomas Shrader maintains a Buy rating on Gain Therapeutics (GANX) due to promising clinical trial results for their drug GT-02287, which shows potential in treating Parkinson’s disease. The drug is well tolerated, with positive patient reception. Upcoming biomarker data may further validate its efficacy. Financially, the company is stable, with growth potential indicated by a discounted cash flow analysis. Roth MKM also reiterates a Buy rating with a $6.00 price target.

    Tip Ranks·
    US
    GANX
    -4.04%
    Tip Ranks·
    US
    GANX
    -4.04%

    Roth MKM Sticks to Its Buy Rating for Gain Therapeutics (GANX)

    Roth MKM's Boobalan Pachaiyappan reiterated a Buy rating for Gain Therapeutics with a $6.00 price target. Despite Pachaiyappan's average return of -10.0% and a 34.31% success rate, the general analyst consensus is a Strong Buy with a $6.80 average price target for Gain Therapeutics.

    Tip Ranks·
    US
    GANX
    -4.04%
    Tip Ranks·
    US
    GANX
    -4.04%

    Gain Therapeutics Reports Continued Progress Amid Financial Challenges

    Gain Therapeutics, Inc. (GANX) reported its Q3 earnings, revealing a net loss of $15.6 million for the nine months ending September 30, 2025, an improvement from $16.6 million in 2024. Despite financial challenges, the biotechnology company has made significant progress in clinical trials, particularly with its lead candidate for Parkinson’s disease, GT-02287. The company raised $11.9 million through public offerings to strengthen its financial position and plans to advance research programs and seek strategic collaborations for further funding.

    Tip Ranks·
    US
    GANX
    -4.04%
    Tip Ranks·
    US
    GANX
    -4.04%

    Gain Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    GANX
    -4.04%
    LB filings·
    US
    GANX
    -4.04%